|
Price: $1.1200
$-0.04 
-3.448%
|
| Day's High:
| $1.175
| Week Perf:
| -2.61 %
|
| Day's Low: |
$ 1.10 |
30 Day Perf: |
22.5 % |
| Volume (M): |
309 |
52 Wk High: |
$ 7.35 |
| Volume (M$): |
$ 347 |
52 Wk Avg: |
$4.22 |
| Open: |
$1.17 |
52 Wk Low: |
$0.86 |
|
|
| Market Capitalization (Millions $) |
74 |
| Shares
Outstanding (Millions) |
66 |
| Employees |
174 |
| Revenues (TTM) (Millions $) |
3 |
| Net Income (TTM) (Millions $) |
-124 |
| Cash Flow (TTM) (Millions $) |
-41 |
| Capital Exp. (TTM) (Millions $) |
4 |
Generation Bio Co
Generation Bio Co is a biotechnology company that is dedicated to developing cutting-edge gene therapy treatments for rare genetic diseases. The company was founded in 2016 by a team of experienced scientists from top institutions like Harvard Medical School, MIT, and the Broad Institute.
The central focus of Generation Bio Co's work is to create gene therapies that utilize adeno-associated viruses (AAV) as vectors to deliver genetic payloads to specific cells in the body. This approach allows for the correction or replacement of defective genes, which is essential for the treatment of countless inherited disorders.
One of the key innovations that sets Generation Bio Co apart is its robust and versatile genetic engineering platform. This platform incorporates various techniques like directed evolution, DNA shuffling, and high-throughput screening to create novel AAV vectors that are highly effective at delivering therapeutic genes to target cells.
The company's founders have a deep commitment to pursuing safe and effective gene therapies. As such, they have developed rigorous safety protocols and are following strict guidelines set by the FDA for clinical trials. Generation Bio Co also emphasizes transparency, ethics, and the involvement of patients and families in the development process.
Currently, Generation Bio Co is working on several promising gene therapy programs across a range of genetic diseases, including hemophilia, phenylketonuria, and spinal muscular atrophy. These therapies have shown impressive results in preclinical studies and are poised to move into clinical trials in the near future.
In summary, Generation Bio Co is a biotechnology company that is focused on developing advanced gene therapies for the treatment of rare genetic diseases. The company is driven by a talented team of scientists who employ innovative technologies to create effective and safe genetic therapies. With a robust pipeline of promising therapies, Generation Bio Co is poised to make a significant impact on the field of gene therapy and the lives of millions of people around the world.
Company Address: 301 Binney Street Cambridge 2142 MA
Company Phone Number: 655-7500 Stock Exchange / Ticker: NASDAQ GBIO
| GBIO is expected to report next financial results on February 22, 2024. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Briacell Therapeutics Corp
The May to July 31, 2023 reporting season has resumed, and many companies, including those in the Major Pharmaceutical Preparations sector, have announced their financial numbers. Among these companies is Briacell Therapeutics Corp, which recently published an operating loss of $-7.705761 million for the financial fourth quarter of 2023. Additionally, Briacell Therapeutics Corp has reported a net deficit of $-14.300 million for the interval between May and July 31, 2023, which is a significant decline compared to the balanced books it maintained during the same period last year.
One noteworthy aspect is that the value of accounts receivable for Briacell Therapeutics Corp is still below the previous year's level; however, there has been some sequential progress. It is also important to mention that the company has observed a shortfall of $-20.30 million and has generated zero revenue during the financial period of 2023.
|
|
Gt Biopharma Inc
The stock market has always been a dynamic and exciting place, filled with ups and downs that keep investors on their toes. Today, we turn our attention to the Major Pharmaceutical Preparations industry and delve into the third quarter of 2023 numbers. Specifically, we examine Gt Biopharma Inc's financial report from July to September 30, 2023, which showcased an operating surplus of $3.122 million.
It's important to note that Gt Biopharma Inc has not cited any revenue yet, making the operating surplus even more impressive. As industry reporters analyze these figures, the prevailing situation of the organization becomes clearer. To truly understand the significance of the third quarter of 2023 earnings season, let's compare it with the same period in 2022.
|
|
Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals Inc, a clinical-stage biotechnology company focused on developing small molecule drugs for viral infections, recently announced its financial results for the July to September 30, 2023, period. During this period, the company reported an increase in losses, which expanded from $1.27 per share a year prior to $1.32 per share. However, it is worth noting that the earnings per share (EPS) improved from -$1.86 in the preceding reporting period.
The revenue for the same period decreased by 6.817% to $18.93 million compared to $20.32 million in the previous reporting period. While sequentially, the revenue advanced slightly by 0.212% from $18.89 million. This decline in revenue could raise concerns, as it may indicate slowing demand for Enanta Pharmaceuticals Inc's products.
|
|
Procyon Corporation
Based on the financial time-frame ending September 30, 2023, Procyon Corporation has experienced significant declines and challenges, leading to a bearish outlook for the company. Depleting orders have played a crucial role in the losses incurred during this period.
The revenue for Procyon Corporation fell by -0.221% to $1.17 million compared to the previous reporting season, where revenue decreased by -2.42% from $1.20 million. This downward trend indicates a constant struggle for the company to maintain a steady revenue stream. It is clear that Procyon Corporation has been facing difficulties in generating consistent income.
|
|
China Health Industries Holdings Inc
China Health Industries Holdings Inc (CHHE) recently announced its financial results for the fiscal period ending September 30, 2023. These results demonstrate the company's ability to achieve top-line growth despite industry-wide revenue reductions. Additionally, CHHE's inventories have declined, indicating potential future demand. This article will outline the facts and set the current financial results into context.
Financial Results Overview:
For the fiscal period ending September 30, 2023, CHHE reported a zero gain of $0.00 per share, compared to a loss of $0.01 per share during the same period a year ago. Sequentially, CHHE improved from a loss of $0.01 per share in the previous quarter. This indicates progress in generating profits and more favorable financial performance.
|
| Per Share |
Current |
| Earnings (TTM) |
-1.96 $ |
| Revenues (TTM) |
0.05 $
|
| Cash Flow (TTM) |
- |
| Cash |
4.41 $
|
| Book Value |
3.52 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-1.96 $
|
| Revenues (TTM) |
0.05 $ |
| Cash Flow (TTM) |
- |
| Cash |
4.41 $
|
| Book Value |
3.52 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
